Evotec SE ADR (EVO)vsEli Lilly and Company (LLY)
EVO
Evotec SE ADR
$1.96
0.00%
HEALTHCARE · Cap: $696.56M
LLY
Eli Lilly and Company
$1,184.91
+0.25%
HEALTHCARE · Cap: $1.06T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 11007% more annual revenue ($79.67B vs $717.28M). LLY leads profitability with a 33.5% profit margin vs -27.5%. EVO appears more attractively valued with a PEG of 1.42. LLY earns a higher WallStSmart Score of 76/100 (B+).
EVO
Hold40
out of 100
Grade: D
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.8%
Fair Value
$34.30
Current Price
$1.96
$32.34 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -28.0% — below average capital efficiency
Revenue declined 16.2%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Return on Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
EVO profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.26 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 40/100), backed by strong 33.5% margins and 47.7% revenue growth. EVO offers better value entry with a 89.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?